Iovance Biotherapeutics, Inc. · NASDAQ:IOVA

Iovance Biotherapeutics — Technical Presentation (June 2021)

6 slides from Iovance Biotherapeutics's technical presentation, Jun 29, 2021

  1. Slide 1: IOV-COM-202 Cohort 3B: Clinical Data for LN-145 in Patients with Metastatic NSCLC

    IOV - COM - 202 Cohort 3B : Clinical Data for LN - 145 in Patients with Metastatic Non - Small Cell Lung Cancer June 29, 2021 © 2021, Iovance Biotherapeutics, Inc 1

  2. Slide 2: 21.4% ORR for LN-145 in Previously Treated Patients with mNSCLC

    21.4% ORR for LN - 145 in Previously Treated Patients with mNSCLC © 2021, Iovance Biotherapeutics, Inc 2 IOV - COM - 202 Cohort 3B (NCT03645928) • After a median study follow - up of 8.2 months, median DOR was not reached • 24/28 patients (85.7%), including all responders, had received ≥2 prior line

  3. Slide 3: Best Percentage Change from Baseline in Target Lesion Sum of Diameters

    Best Percentage Change from Baseline in Target Lesion Sum of Diameters (1) for Evaluable Patients (n=24) © 2021, Iovance Biotherapeutics, Inc 3 IOV - COM - 202 Cohort 3B (NCT03645928) (1) As assessed by investigator using RECIST 1.1. (2) Patient 2 is reported as a CR based on a negative FDG - PET sc

  4. Slide 4: Time to Response for Confirmed Responders

    (1) As assessed by investigator using RECIST 1.1. (2) Patient 2 is reported as a CR based on a negative FDG - PET scan by investigator. CR, complete response; PD, progressive disease; PD - L1, programmed death ligand - 1; PR, partial response; RECIST, Response Evaluat ion Criteria in Solid Tumors; T

  5. Slide 5: Conclusions: LN-145 in Advanced or Metastatic NSCLC

    • Treatment options are limited for patients with metastatic NSCLC who progress or relapse after standard - of - care front - line therapies, including platinum - doublet chemotherapy and ICI or TKI • In 28 patients with advanced or metastatic NSCLC who progressed after systemic therapy (including I

  6. Slide 6: IOV-COM-202 Cohort 3B: Background

    • Nearly 70% of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis (1) • LN - 145, an autologous TIL cell therapy, is being investigated (IOV - COM - 202, NCT03645928) for the treatment of patients with locally advanced or metastatic NSCLC − Patients mus

Iovance Biotherapeutics — Technical Presentation (June 2021) on 6ix